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Telomeres are nucleoprotein structures at the end of linear chromosomes 
composed by TTAGGG DNA tandem repeats and a six-protein complex, called shelterin, 
which protects telomeres and prevents them from being recognized as dsDNA brakes 
and trigger DNA damage response, leading to cellular apoptosis or senescence. 
Telomeres are located above coding regions and protect chromosomes from 
degradation and fusion events. However, due to incomplete replication of the ends of 
eukaryotic linear chromosomes, telomeres shorten with each round of cell division, and 
if reaching a critically short length, the cell viability would be compromised. 
TRF1 is an essential component of shelterin, with important roles in telomere 
protection and telomere replication. TRF1 deficiency in the context of different mouse 
tissues leads to loss of tissue homeostasis owing to impaired stem cell function. Recent 
reports suggest that TRF1 levels decrease during in vitro cellular aging induced via cell 
passaging. Furthermore, and subsequent overexpression of TRF1 in these “aged” cells 
at late passages reduced DNA damage at telomeres and decreased senescence, 
suggesting that age-related loss of TRF1 can contribute to aging phenotype in vitro. 
Therefore, we first addressed whether TRF1 levels decrease is associated with 
aging in vivo. We measured TRF1 levels in tissues of different ages and found that TRF1 
levels decrease during organismal aging both in mice and humans. 
To test if natural TRF1 loss with age contributes to organismal aging impairments 
we overexpressed TRF1 via TRF1 gene therapy in both adult (1 year old) and old (2 
years old) mice and studied its effects on aging process. To this end, we used the non-
integrative adeno-associated serotype 9 vector (AAV9), which transduces the majority 
of mouse tissues allowing for moderate and transient TRF1 overexpression. AAV9-TRF1 
gene therapy significantly prevented age-related decline in neuromuscular function, 
glucose tolerance, cognitive function, maintenance of subcutaneous fat, and chronic 
anemia. Interestingly, although AAV9-TRF1 treatment did not significantly affect median 
telomere length, we found a lower abundance of short telomeres and of telomere-
associated DNA damage in some tissues. Together, these findings suggest that rescuing 
naturally decreased TRF1 levels during mouse aging by using AAV9-TRF1 gene therapy 
results in an improved mouse health span. 
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Los telómeros son estrucruras nucleoprotéicas que se encuentran en los extremos 
de los cromosomas lineales, y que consisten en repeticiones en tándem de la secuencia 
de ADN, TTAGGG y un complejo de seis proteínas, llamado shelterina, que protege al 
ADN telomérico y evita que estos sean reconocidos como rupturas de doble cadena de 
ADN, lo que desencadenaría una respuesta de daño al ADN, que podría conducir a la 
apoptosis o senescencia celular. Los telómeros están ubicados encima de las regiones 
codificantes y protegen a los cromosomas de la degradación y fusiones cromosómicas. 
Sin embargo, debido a la replicación incompleta de los extremos de los cromosomas 
lineares eucarióticos, los telómeros se acortan por cada ciclo celular, y a una longitud 
críticamente corta se comprometería la viabilidad celular.  
TRF1 es un componente esencial de complejo shelterina, con funciones 
importantes en la protección y la replicación de los telómeros. Se ha demostrado que la 
deficiencia de TRF1 en el contexto de diferentes tejidos de ratón conduce a la pérdida 
del homeostasis del tejido debido a la función deteriorada de las células madre. 
Publicaciones recientes sugieren que los niveles de TRF1 disminuyen durante el 
envejecimiento celular in vitro inducido a través de los pases de células. Además, la 
posterior sobreexpresión de TRF1 en estas células "envejecidas" en pasajes tardíos 
redujo el daño del ADN en los telómeros y disminuyó la senescencia, lo que sugiere que 
la pérdida de TRF1 relacionada con la edad puede contribuir al fenotipo de 
envejecimiento in vitro. 
Por lo tanto, en nuestro trabajo primero abordamos si disminución de los niveles 
de TRF1 se asocia con el envejecimiento in vivo en ratones. Para ello, medimos los 
niveles de TRF1 en tejidos de diferentes edades y encontramos que los niveles de TRF1 
disminuyen durante el envejecimiento del organismo tanto en ratones como en 
humanos. 
Para evaluar si la pérdida natural de TRF1 durante el envejecimiento contribuye 
al empeoramiento relacionado con la edad, sobre-expresamos TRF1 a través de la 
terapia génica con el gen de TRF1 en ratones adultos (1 año de edad) y viejos (2 años 
de edad) y estudiamos sus efectos sobre el proceso de envejecimiento. Para tal fin, 
utilizamos el vector serotipo 9 del virus adeno-asociado no integrativo (AAV9), que 
transduce la mayoría de los tejidos del ratón, permitiendo así, una sobreexpresión 
moderada y transitoria de TRF1.  
La terapia génica con AAV9-TRF1 evitó significativamente, la disminución en las 
funciones neuromusculares y cognitivas, la tolerancia a la glucosa, el mantenimiento de 
la grasa subcutánea y la anemia crónica, todos ellos factores relacionados con la edad. 
Adicionalmente, aunque el tratamiento con AAV9-TRF1 no afectó significativamente la 
longitud media de los telómeros, encontramos una menor abundancia de telómeros 
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cortos y daño del ADN asociado a los telómeros en algunos tejidos. En resumen, estos 
resultados sugieren que el rescate de los niveles de TRF1, que disminuyen de forma 
natural durante el envejecimiento del ratón, mediante el uso de la terapia génica con 
AAV9-TRF1 resultaría en una mejor salud del ratón. 
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AAP – assembly-activating protein 
AAV – adeno-associated virus 
AAVR – AAV receptor 
ALT – alternative lengthening of telomeres 
alt-NHEJ – alternative NHEJ 
APCs – antigen-presenting cells 
ATM – ataxia telangiectasia mutated 
ATR – ataxia telangiectasia and Rad3 related 
a. u. – arbitrary units 
AUC – area under the curve 
53BP1 – p53-binding protein 1 
BR – basic region 
BMD – bone mineral density 
CAG –CMV + chicken b-actin + rabbit b-globin 
CBA – chicken β-actin 
cDNA – complementary DNA 
CLIC – clathrin-independent carrier 
CMV – cytomegalovirus 
CHK1 – checkpoint kinase 1 
CHK2 – checkpoint kinase 2 
c-NHEJ – classic NHEJ 
DDR – DNA-damage response 
DEXA – Dual Energy X-ray Absorptiometry 
D-loop – displacement loop 
DNA – deoxyribonucleic acid 
dsDNA – double-stranded DNA 
DSB – double-strand break 
EF1a – elongation factor 1a 
EM – electron microscopy  
FISH – fluorescence in situ hybridisation  
GAPDH – glyceraldehyde-3-phosphate dehydrogenase 
GEECs – glycosylphosphotidylinositol- anchored protein enriched endosomal 
compartments 
GTT – glucose tolerance test 
Hb – hemoglobin 
Hct – hematocrit 
HDR – homology-directed repair 
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HOMA-IR – homeostatic model assessment of insulin resistance 
HT Q-FISH – high-throughput Q-FISH 
IP-GTT – intra-peritoneal glucose tolerance test 
ITR – inverted terminal repeat 
IV – intravenous 
miRNA - microRNA 
NHEJ – non-homologous end joining 
NLS – nuclear localization signal 
NPC – nuclear pore complex 
Oct3/4 – octamer-binding transcription factor 3/4 
ORC – origin recognition complex 
ORF – open reading frame 
PBMC – peripheral blood mononuclear cell 
PCR – polymerase chain reaction 
PI – post-injection 
PLA1 – phospholipase A1 
PLA2 – phospholipase A2 
Pol II P – polymerase II promoter 
Pol III P – polymerase III promoter 
POT1 – protection of telomeres protein 1 
Q-FISH – quantitative fluorescence in situ hybridisation  
rAAV vector – recombinant adeno-associated viral vector 
RAP1 – repressor / activator protein 1 
RBC – red blood cell 
RNA – ribonucleic acid 
RT-qPCR – reverse transcription quantitative PCR 
SEM – standard error of measurement 
shRNA – short hairpin RNA 
snRNA – small nuclear RNA  
ssDNA – single-stranded DNA 
SV40 – simian virus 40  
TERC – telomerase RNA component 
TERT – telomerase reverse transcriptase 
TIF – telomere dysfunction-induced foci 
TIN2 – TRF1- and TRF2-interacting nuclear protein 2 
TGN – trans-Golgi network 
T-loop – telomeric loop 
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TRF1 – telomeric repeat-binding factor 1 
TRF2 – telomeric repeat-binding factor 2 
TRFH – telomeric repeat-binding factor homology domain 
TPP1/ACD – TINT1/PTOP/PIP1 / adrenocortical dysplasia homolog 
TZAP – telomeric zinc finger-associated protein 
XPF – Xeroderma Pigmentosum Group F 
yH2AX – gamma phosphorylated histone H2AX 
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I. TELOMERES 
1. TELOMERES AND THEIR FUNCTION 
Mammalian telomeres are heterochromatic structures at the end of linear 
chromosomes that consist of TTAGGG repeats bound by an array of associated proteins 
known as shelterin, which prevent chromosome ends from being recognised as double-
strand DNA breaks and from chromosome end-to-end fusions (Blackburn 2000; de 
Lange 2005). Telomere length varies between the species, with an average length 15-
20 kb in human germline and 25-150 kb in laboratory mice. 
Telomeres evolved in eukaryotic cells as a solution to the “end-replication 
problem”, which refers to the incomplete DNA replication of the ends of linear 
chromosomes by the DNA replication machinery (Watson 1972; Olovnikov 1973), thus 
leading to telomere shortening with each round of cell division (Harley et al. 1990). To 
start a DNA synthesis DNA polymerase requires a 3’-OH group, which in eukaryotic cells 
is provided by RNA-primers placed on unzipped ssDNA.  Upon the end of replication, 
RNA primers are removed and the gaps are filled by deoxyribonucleotides. However, 
when removing primer from a 5’-very end of chromosome there is no 3’-OH group above 
to prime DNA synthesis, giving rise to the single strand 3’ G-overhang (Fig. 1). In this 
way DNA getting shorter with each cell division.  
 
 
 
 
 
 
 
Figure 1. End-replication problem. 
Incomplete DNA replication of the lagging strand leads to 3’ overhangs formation.  
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2. MECHANISMS OF TELOMERE ELONGATION 
TELOMERASE 
There is an active form to maintain telomere length carried out by a 
ribonucleoprotein called telomerase. Telomerase is a reverse transcriptase (TERT). It 
elongates telomeres de novo by adding telomeric repeats on chromosome ends, using 
as template an RNA component (TERC), and thus preventing telomere erosion (Greider 
& Blackburn 1985).  It hybridises with a single strand overhang of DNA and telomerase 
synthesizes the DNA strand complementary to its RNA subunit, translocates to the end 
of the synthesized strand and the process repeats. When a single stand overhang has 
been elongated, DNA primase synthesizes RNA primer near the 3 prime end and DNA 
polymerase fills the space (Fig. 2). Telomere elongation by telomerase is regulated by 
cell cycle and occurs at S phase, being coupled to DNA replication (Ten Hagen et al. 
1990; Wright et al. 1999; Marcand et al. 2000; Zhao et al. 2009).    
 
 
 
ALTERNATIVE LENGTHENING OF TELOMERES (ALT) 
 ALT is an alternative-to-telomerase telomere lengthening pathway, used by some 
cancer cell in the absence of telomerase activity  (Bryan & Reddel 1997; Henson et al. 
2002), which can also take place in normal somatic mouse tissues (Herrera et al. 2000; 
Neumann et al. 2013). ALT is based on recombination-mediated elongation and occurs 
via invasion of one telomere by a ssDNA of another telomere, which serves as a template 
to synthetize new repeats (Dunham et al. 2000; Henson et al. 2002).  
Figure 2. Telomere elongation by 
telomerase. 
Telomerase (in yellow) (TERT) using its 
RNA component (TERC) as a template 
elongates 3’ telomeric overhang. Then 
RNA primase synthetizes RNA primer (in 
green) and DNA polymerase completes 
de novo the synthesis of telomeric 
repeats on the complementary strand. 
TERT 
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3. T-LOOP AS A TELOMERIC SECONDARY STRUCTURE 
Free DNA end at linear chromosome termini would be vulnerable to different 
cellular processes such as DNA repair. However, strand 3’ G-overhang does not always 
exist as a free extension, but has been proposed to fold back invading the double-
stranded telomeric region and forming so-called telomeric (T)-loop and displacement (D)-
loop structures (Fig. 3A). Sequestration of the G-overhang in the T-loop helps to 
distinguish chromosome ends from sites of DNA damage, preventing a DNA damage 
response (DDR), inappropriate DNA repair and protecting chromosomes from 
degradation (Griffith et al. 1999). 
It is important to note that replication of the telomere on the leading strand will end 
up in a blunt end. The absence of 3’ G-overhang would make impossible the elongation 
telomeres by telomerase, due to the fact that telomerase is incapable of extending the 
blunt-end DNA duplex (Lingner & Cech 1996). Interestingly is was shown that most of 
eukaryotic chromosomes have 3’ G-overhangs on both sides. Evidence suggests that 
the blunt-side end of the chromosome is processed by nucleases (Wellinger et al. 1996; 
Dionne & Wellinger 1996), such as Apollo (Wu et al. 2010), forming likewise a 3’-G-
overhang and making it possible to form a protective T-loop structure at both ends of the 
chromosome. 
T-loop structures for the first time have been shown in vitro as a lariat-like 
structures on electron microscopy (EM) images, obtained after incubation of DNA 
structures, which were mimicking telomeric the very end DNA, with baculovirus-derived 
human TRF2 (Fig. 3B) (Griffith et al. 1999). Existence of the T-loops was further 
confirmed in vivo in telomere-enriched fractions from psoralen cross-linked nuclei from 
different mouse and human cell types (Fig. 3C-D) (Griffith et al. 1999). In the same study 
it was also demonstrated that T-loop size in mammalian cells correlates with telomere 
length (Griffith et al. 1999). 
                   
 
 
Figure 3. T-loop structure. 
(A) Model of the T-loop DNA structure, adopted from 
(de Lange 2004). (B-D) EM visualisation of T-loops 
observed in vitro (B) and in vivo in HeLa (C) and 
mouse liver primary cells (D) (Griffith et al. 1999). 
  
D-loop 
B C D 
A T-loop 
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4. TELOMERIC NUCLEOPROTEIN ORGANIZATION. SHELTERIN COMPLEX 
Telomere protection is achieved by a presence of the shelterin complex (Fig. 4A-
B). Shelterin caps and compacts telomeres, inducing formation and maintaining a T-loop 
structure, thereby protecting telomeres from DNA-repair machinery. Blocking activation 
of ATM and ATR kinases, shelterin prevents nonhomologous end joining (NHEJ) and 
homology-directed (HDR) DNA repair pathway activation and a cell cycle arrest (de 
Lange 2002; d’Adda di Fagagna et al. 2003; d’Adda di Fagagna et al. 2004; de Lange 
2005; Muñoz et al. 2006; Palm & de Lange 2008; Martínez et al. 2009).  
Shelterin has been also proposed in the recruitment of telomerase to telomeres 
(Tejera et al. 2010). On the other hand, shelterin is behaving like a cis-acting inhibitor of 
telomere elongation. The amount of the shelterin on telomere is proportional to telomere 
length. Highly abundant shelterin on the very long telomeres blocks telomerase activity, 
preventing unnecessary telomere elongation (Smogorzewska & de Lange 2004; de 
Lange 2005). Interestingly, it was recently described a new player in telomere length 
regulation – Telomeric Zinc finger-Associated Protein (TZAP). TZAP is a specific 
telomere-associated protein, which binds to long telomeres and initiates telomere 
trimming (Li et al. 2017).  
Shelterin consists of six proteins – TRF1 (telomeric repeat-binding factor 1) (Zhong 
et al. 1992; Chong et al. 1995), TRF2 (telomeric repeat-binding factor 2) (Bilaud et al. 
1997; Broccoli et al. 1997), POT1 (protection of telomeres protein 1) (Baumann & Cech 
2001), TIN2 (TRF1- and TRF2-interacting nuclear protein 2) (Kim et al. 1999), TPP1 (or 
ACD, adrenocortical dysplasia homolog) (Liu et al. 2004; Ye et al. 2004) and 
RAP1(repressor / activator protein 1) (Li et al. 2000) (Fig. 4A-B). 
 
 
 
 
 
 
Figure 4. Shelterin complex. 
(A) Shelterin complex on the T-loop structure, and (B) shelterins and their interconnection. 
B A 
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TRF1 
TRF1 is one of the key components of the shelterin complex (Bianchi et al. 1999). 
TRF1 is the first of the shelterin proteins discovered (Zhong et al. 1992; Chong et al. 
1995). Murine TRF1 is a 56 kD and 421 amino acids protein, (human: 50,2 kDa; 439 aa), 
which specifically binds to a dsDNA as a homodimer (Zhong et al. 1992; Bianchi et al. 
1997; Court et al. 2005). 
TRF1 contains four functional domains: an acidic N-domain, involved in protein-protein 
interactions, the TRF homology (TRFH) dimerization domain, which facilitates 
homodimerization and interaction with TIN2 protein, the nuclear localization signal (NLS) 
domain and one C-terminal SANT/MYB DNA binding domain, which recognizes 5’-
YTAGGGTTR-3’ sequence in a double-strand DNA with a high specificity (Chong et al. 
1995) (Fig. 5A-B). TRF1 contains a single MYB domain. Interestingly, two MYB motifs 
are required for a stable TRF1-DNA complex formation, which means the formation 
of TRF1 homodimers fulfils this criteria (Bianchi et al. 1997). TRF1 does not bind 
to regions outside telomeric repeats, and that its binding is restricted to telomeric 
regions both in conditions of normal or critically short telomeres (Garrobo et al. 
2014). 
 
 
 
 
 
 
 
 
 
 
Figure 5. TRF1 domain organization 
(A) Scheme of domains of human TRF1 (hTRF1) and it homology with mouse TRF1 (mTRF1) 
(Bianchi et al. 1997) 
(B) TRF1 dimer formation through protein-protein interaction via TRFH homology dimerization 
domains. Binding to telomeric DNA occurs through MYB domains. D/E is a D/E-rich N-terminal 
acidic domain (Diotti & Loayza 2011).  
A 
B 
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Through its interaction with TIN2, TRF1 binds to TRF2, playing an important role 
in shelterin complex assembly (Xin et al. 2008; Diotti & Loayza 2011) (Fig. 4A-B). TRF1 
is important both to prevent telomere fusions as well as for the replication of telomeric 
regions (Sfeir et al. 2009).  Genetic manipulations with TRF1 overexpression 
demonstrated that TRF1, when systematically overexpressed, acts as a negative 
regulator of telomere length, mediating telomere cleavage by XPF nuclease (Muñoz et 
al. 2009). However, many in vitro and in vivo studies have assessed the importance of 
TRF1 in the healthy cellular and tissue homeostasis and showed that its insufficiency 
likewise leads to dramatic damages. In particular, deletion of TRF1 in mouse embryonic 
fibroblasts (MEFs) results in induction of senescence through activation of ATR/CHK1 
and ATM/CHK2 checkpoint pathways, as well as in chromosome fusions and 
multitelomeric signals (aberrant number of telomeric signals per chromosome end) 
(Martínez et al. 2009; Sfeir et al. 2009). Homozygous deletion of TRF1 in mice leads to 
embryonic lethality, caused by severe telomere dysfunction (Karlseder et al. 2003). 
Importantly, these effects of TRF1 abrogation are independent of telomere length, as 
TRF1 deletion uncaps telomeres independently of telomerase and cell division 
(Karlseder et al. 2003; Martínez et al. 2009; Sfeir et al. 2009). Heterozygous deletion of 
TRF1 in mice leads to telomere and overall DNA damage and increased tumor incidence 
(Hartmann et al. 2016). In addition, conditional TRF1 abrogation in various mouse 
tissues has demonstrated the importance of TRF1 for tissue regeneration and tissue 
homeostasis (Beier et al. 2012; Povedano et al. 2015; Schneider et al. 2013; Martínez 
et al. 2009). Indeed, high TRF1 levels mark stem cell compartments as well as pluripotent 
stem cells, and are essential to induce and maintain pluripotency (Schneider et al. 2013). 
In this regard, it was previously shown that TRF1 is a direct transcriptional target of the 
pluripotency factor Oct3/4 (Schneider et al. 2013).  
TRF2 
TRF2 was identified by its homology with TRF1 in the database (Bilaud et al. 1996; 
Broccoli et al. 1997). TRF shares with TRF1 a similar architecture and a common domain 
structure in TRFH dimerization domain and MYB DNA binding domain (Bilaud et al. 
1996; Broccoli et al. 1997; Court et al. 2005)  (Fig. 6). As well as TRF1, TRF2 binds 
directly to a dsDNA as a homodimer (Court et al. 2005). However, despite these 
similarities, TFR2 plays a different role at telomeres.    
TRF2 plays a major role in the T-loop formation and maintenance (de Lange 2002; 
Doksani et al. 2013; Griffith et al. 1999; Stansel et al. 2001). Mice deficient for TRF2 are 
early embryonic lethal (Celli & de Lange 2005). TRF2 inhibition results disruption of the 
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T-loop and in further loss of the 3’ overhang, leading to ATM DNA damage signalling and 
activation non-homologous end-joining (NHEJ) DNA damage response (Celli & de Lange 
2005; Sfeir et al. 2009). This provokes extensive chromosome end-to-end fusions, 
further leading to rupture of formed dicentric chromosomes and induction of apoptosis 
(Celli & de Lange 2005; Karlseder et al. 1999). TRF2 overexpression, likewise TRF1, 
leads to telomere degradation, mediated by XPF nuclease recruited to telomeres (Muñoz 
et al. 2005; Muñoz et al. 2006; Blanco et al. 2007). 
 
  
 
 
 
POT1 
POT1 is a shelterin, which possesses high specificity for the single-strand telomeric 
DNA and binds 3’ G-overhang and displaced G-strand at the D-loop (Palm & de Lange 
2008; Lei et al. 2004). POT1 is connected with the shelterin complex through binding to 
TPP1 (Fig. 4A-B). POT1 plays an important role in inhibition of DNA damage response 
and ATR signalling at telomeres, blocking the binding of RPA to telomeres (Denchi & de 
Lange 2007; Takai et al. 2011). POT1 protects 3’ overhang and shapes telomere ends, 
determining the sequence of the 5’ telomeric end (Hockemeyer et al. 2005), as well as 
playing a role in telomere length regulation (Loayza & De Lange 2003; Ye et al. 2004). 
Unlike human POT1, mice contain two isoforms – POT1a and POT1b, where 
POT1a has been proposed to be required to repress DDR and activation of ATR at 
telomeres, whereas POT1b regulates 3’ ssDNA overhangs (Hockemeyer et al. 2006; Wu 
et al. 2006). Lack of POT1a results in embryonic lethality, whereas mice lacking POT1b 
are viable and fertile (Hockemeyer et al. 2006).   
TPP1 
TPP1, encoded by the Acd gene, mediates POT1 binding to the rest of the 
sheltering complex (Fig. 4A-B) and to telomeres, contributing to a normal function of 
POT1/POT1a and POT1b and therefore playing a role in telomere protection and 
Figure 6. Scheme or TRF1 and TRF2 protein domain structure. 
Homology between TRF homology domain (TRFH) and MYB DNA binding domain (MYB), 
shown as a percentage (Court et al. 2005). 
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preventing DDR at telomeres (Tejera et al. 2010; Kibe et al. 2010). It was also shown a 
role of TPP1 in recruitment of telomerase to telomeres (Tejera et al. 2010). Moreover 
human cells lacking TPP1 fail to recruit telomerase to telomeres, demonstrating the need 
of TPP1 for telomerase-dependent telomere elongation (Abreu et al. 2010). Deletion of 
TPP1 results in early embryonic lethality (Kibe et al. 2010). 
TIN2 
TIN2 binds to TRF1 and TRF2, acting as a bridge between two homodimers (Fig. 
4A-B) (Kim et al. 2004). TIN2 also recruits TPP1/POT1 to the complex and loads it on 
telomeres (Ye et al. 2004; Takai et al. 2011). It was shown that the role of TIN2 in 
connecting various shelterin components is relevant to protection of telomeres from ATR 
and ATM signalling, ensured by TPP1/POT1 and TRF2 shelterins (Takai et al. 2011).  
RAP1 
RAP1 is proposed to be recruited to telomeres by TRF2 (Fig. 4A-B) (Li et al. 2000; 
Li & de Lange 2003). RAP1 is irrelevant for telomere capping, however it deficiency leads 
telomere recombination and frailty (Martinez et al. 2010; Sfeir et al. 2010). RAP1 binds 
both to telomeres and extra-telomeric TTAGGG sites, majority of which are found at 
intragenic positions or at the close proximity to gene-coding regions (Martinez et al. 
2010). In this context RAP1 possesses several extra-telomeric functions such as 
silencing of subtelomeric genes and transcriptional regulation of genes involved in 
cancer, cell adhesion and metabolism (Martinez et al. 2010; Teo et al. 2010). 
SHELTERIN ACCESSORY FACTORS 
There are approximately 200 proteins involved in different aspects of telomere 
biology, contributing to their maintenance and to chromosome protection (Déjardin & 
Kingston 2009).  A large number of them is recruited to telomeres through the shelterin 
complex, named as shelterin accessory factors. Most of accessory factors are transiently 
recruited to telomeres, whereas shelterin is constantly presented throughout the cell 
cycle. This factors are involved in DNA damage response (ATM kinase, MRE11-RAD50-
NBS1 (MRN) complex) and DNA repair (Ku70/80 heterodimer, XPF/ERCC1, Apollo 
exonuclease), DNA replication (origin recognition complex (ORC), RecQ helicases) or 
chromatin structure (HP1 proteins), etc. Losses of shelterin accessory factors impair 
telomere maintenance and can lead to telomere shortening, loss or telomere fusion. 
Reviewed in (Palm & de Lange 2008; Burla et al. 2015). 
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5. CONSEQUENCES OF TELOMERE DYSFUNCTION 
Although telomerase is aimed to maintain telomere length, mammalian cells stop 
expressing telomerase in the majority of tissues after birth (Blasco et al. 1995; 
Schaetzlein et al. 2004), leading to progressive telomere erosion throughout the lifespan 
of the organism. Telomerase expression in the adult organism remains restricted to a 
few cell types, such as germ and stem cells. Furthermore it was demonstrated that 
telomerase activity in stem cells is insufficient to prevent telomere shortening with 
continuous tissue renewal and proliferation (Broccoli et al. 1995; Chiu et al. 1996; 
Hiyama et al. 1996; Engelhardt et al. 1997; Wright et al. 2006; Brümmendorf & Balabanov 
2006; Hiyama & Hiyama 2007).  
When telomeres shorten below a threshold length or have lost shelterin protection, 
they are not able anymore to maintain the T-loop protective organization and become 
dysfunctional. Telomeric ends become indistinguishable from a double-strand DNA 
break (dsDB) and are exposed to endonucleases and DNA repair machineries, activating 
DNA damage response (DDR) at chromosome ends. DNA damage signalling cascade 
eventually leads to the activation of apoptotic and/or cellular senescence programs and 
thus to the deregulation of many functional processes (Martens et al. 2000; O’Sullivan & 
Karlseder 2010; Blackburn 2000).  Two signalling pathways play a central role in the 
response to DNA breaks: ATM, which is activated by DSBs (Shiloh 2003), and ATR 
kinase pathway, activated by lesions after they have been proceeded to single strand 
intermediates (Zou & Elledge 2003). Activation of either pathway leads to H2AX histone 
phosphorylation on Ser139 (yH2AX). These activated sites of DNA damage at the 
chromosome ends can be visualized at telomeres as so-called Telomere Dysfunction 
Induced Foci (TIF). Once activated ATM and ATR pathways induce phosphorylation of 
checkpoint protein kinases CHK2 and CHK1. ATM and ATR pathways demonstrate an 
active cross talk in response to DNA damage (Cuadrado et al. 2006). Eventually they 
both lead to p53 phosphorylation (d’Adda di Fagagna et al. 2003; Gire et al. 2004; Guo 
et al. 2007; Denchi & de Lange 2007). Phosphorylation of p53 stimulates expression of 
the cyclin-depzendent kinase inhibitor p21, leading to senescence, or activates p53-
dependent apoptosis, possessing a role in tumor suppression in cells with dysfunctional 
telomeres (Deng et al. 2008). Furthermore unprotected telomeric ends can be sensed 
by classical-NHEJ (c-NHEJ), alternative NHEJ (alt-NHEJ) and homology-directed repair 
(HDR) pathways (Sfeir & de Lange 2012). HDR provokes rapid changes in telomere 
length, telomere loss and in telomeric or non-telomeric sequence exchanges, resulting 
in genome instability and leading to deletions, inversions and translocations (de Lange 
2005; de Lange 2009). C-NHEJ and alt-NHEJ repair lead to chromosome fusions and 
 
  
36 
 
 
formation of dicentric chromosomes, the rapture of which can lead to apoptosis or trigger 
genome instability and cancer (Martínez & Blasco 2010; O’Sullivan & Karlseder 2010) 
(Fig. 7).  
 
 
6. TELOMERES AND AGING 
Aging is characterized by a time-dependent functional impairment of the organism 
in which several molecular pathways have been demonstrated to play a causal role 
(reviewed in Gladyshev 2016; López-Otín et al. 2013).  Current efforts are directed at 
specifically targeting these fundamental aging events since intervening in these 
molecular pathways could delay or prevent age-related diseases and increase lifespan  
(reviewed in López-Otín et al. 2013). Telomere shortening has been identified as one of 
the primary hallmarks of aging (Blasco 2005; Martínez & Blasco 2017; López-Otín et al. 
2013). Telomere shortening has been demonstrated to be sufficient to trigger age-related 
pathologies and shorten lifespan in mice (Blasco et al. 1997; Lee et al. 1998; Blasco 
2005). Similarly, humans suffering from the so-called telomere syndromes, characterized 
by mutations in telomerase and other telomere maintenance genes, also show 
Figure 7. Schematic representation of the pathways activated upon telomere dysfunction 
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premature age-related pathologies (Armanios & Blackburn 2012; Gilson & Londoño-
Vallejo 2007). 
 Telomerase re-activation has been envisioned as a strategy to maintain 
telomeres, and therefore, to increase the proliferative potential of tissues, both in the 
telomere syndromes and in age-related conditions. Constitutive TERT expression in the 
context of cancer resistant mice was shown to be sufficient to maintain longer telomeres 
and less DNA damage with aging, as well as to delay age-related pathologies and 
increase mouse longevity by 40% (Tomás-Loba et al. 2008). More recently, telomerase 
over-expression in adult and old wild type mice by using non-integrative gene therapy 
vectors was sufficient to delay physiological aging and increase both median and 
maximum lifespan in wild-type mice in the absence of increased cancer (Bernardes de 
Jesus et al. 2012). Telomerase reactivation in mice with critically short telomeres owing 
to telomerase deficiency was also able to reverse tissue degeneration (Jaskelioff et al. 
2011). Finally, small molecule telomerase activators such as TA-65 have been also 
described to delay some features of aging (Harley et al. 2011; Bernardes de Jesus et al. 
2011).  
Intriguingly, TRF1 levels have been recently shown to decrease with cell 
passaging, which simulates an aging process in vitro, for the first time showing that age 
intrinsic mechanisms lead to a reduction of TRF1 levels. Subsequent overexpression of 
TRF1 in “aged” cells at late passages reduced DNA damage at telomeres to the level 
observed in the “young” cells and decreased senescence, suggesting that decreased 
TRF1 levels with cell passaging can contribute to senescence and aging phenotype in 
vitro (Hohensinner et al. 2016).  
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II. rAAV GENE THERAPY 
1. ADENO-ASSOCIATED VIRUS (AAV)  
Adeno-associated virus (AAV) is a small (25 nm) replication-defective 
nonenveloped virus belonging to the family Parvoviridae. The AAV capsid is composed 
of 60 subunits compiled by three capsid proteins VP1, VP2 and VP3 in proportions of 
about 1:1:10, arranged with T = 1 icosahedral symmetry. VP1-3 share overlapping 
sequence, differing only at their N termini (Xie et al. 2002). AAV capsid packages a 
single-stranded (ssDNA) genome of approximately 4.7 kb size, with three open reading 
frames (ORFs), rep, cap, and assembly-activating protein (AAP), flanked by two inverted 
terminal repeats (ITRs). ITRs are sequences comprised by 145 bases each, which are 
palindromic and able to form a hairpin structure leading to self-priming and allowing 
primase-independent synthesis of the second DNA strand, thus are essential for efficient 
replication of viral genome (Bohenzky et al. 1988) as well as playing a role in viral packing 
(McLaughlin et al. 1988; Zhou & Muzyczka 1998). Rep gene encodes 4 regulatory 
proteins Rep40, Rep52, Rep68, and Rep72, involved in AAV genome replication. The 
cap gene, by means of alternative splicing and initiation of translation, gives rise to three 
structural proteins VP1-3 which form AAV capsid (Berns 1990). AAP is translated from 
the aap gene located in an alternate ORF overlapping the cap gene. It is required for 
AAV capsid assembly and is essential for virus reproduction (Sonntag et al. 2010; 
Naumer et al. 2012) (Fig. 8).  
Figure 8. Representation of the wild-type adeno-associated virus genome (wt-AAV) 
(Saraiva et al. 2016). 
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2. rAAV AS A GENE THERAPY VECTOR  
Interest in AAV virus was born in mid-1980s when it was first recognized that AAV 
can be used as a gene therapy vector (Tratschin et al. 1984; Hermonat & Muzyczka 
1984) and to date they recognized as one of the most promising strategy for  gene 
delivery.  
In recombinant AAV vectors (rAAV) viral genome is substituted by a transgene 
cassette, <4,5 kb in length, cloned between 2 ITRs. Transgene cassette can correspond 
to a protein-coding complementary DNA (cDNA), microRNA (miRNA), or small nuclear 
RNA (snRNA) driven by a polymerase II promoter (Pol II P), or either to two inverted 
repeated sequences (sense and antisense), separated by a loop spacer, which upon 
transcription from a polymerase III promoter (Pol III P) form RNA which folds into a short 
hairpin RNA (shRNA) (Fig. 9) (Zacchigna et al. 2014). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Schematic representation of AAV and recombinant AAV vectors.  
(A) Genomic organization of wild-type AAV, which contains three ORFs – rep, cap, and 
assembly-activating protein (AAP), flanked by two inverted terminal repeats (ITRs). (B) AAV 
vector, expressing of therapeutic gene (protein-coding complementary DNA (cDNA), 
microRNA (miRNA), or small nuclear RNA (snRNA)), driven by a polymerase II promoter (Pol 
II P) and cloned into plasmid. (C) Expression of short hairpin RNAs (shRNAs). Inverted 
repeated sequences - antisense (AS) and sense (S), separated by a loop spacer, transcribed 
from a Pol III P. The resulting RNA folds back into a hairpin structure (shRNA), which is 
recognized and processed by the cellular endonuclease Dicer into a small interfering RNA 
molecule. (Zacchigna et al. 2014) 
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In many therapeutic strategies it is often desirable to achieve broad transgene 
expression in various tissues. Strong and constitutively active promoter assures high-
level expression of the transgene. Commonly used promotors for this scenario are CMV 
(cytomegalovirus) promoter/enhancer, EF1a (elongation factor 1a), SV40 (simian virus 
40), CBA (chicken β-actin) and CAG (derivative from CMV, chicken b-actin, rabbit b-
globin). Among these constitutive promoters CAG is the strongest to achieve transgene 
expression in most cell types (Powell et al. 2015; Naso et al. 2017). However, in the 
scenario when it is important to achieve cell- or tissue-specific expression, the vector 
could be delivered locally, or a tissue-specific promoter can be used. 
It is well known that AAV genome can integrate site-specifically into human 
genome via a non-homologous recombination pathway (Kotin et al. 1990; Kotin et al. 
1991; Samulski et al. 1991). It is possible due to homology between Rep-binding element 
located on ITR of the virus and the AAVS1 sequence discovered on the human 
chromosome 19 (Kotin et al. 1992; Vance et al. 2015). However, to guarantee safety of 
the rAAV for using as a gene therapy vector, Rep gene as well as the element required 
for site-specific integration are removed from AAV genome. Therefore rAAV exists in an 
extrachromosomal state, preventing random mutagenesis much may be induced upon 
insertion (Vance et al. 2015). 
3. rAAV CELLULAR TRANSDUCTION MECHANISM  
Use of recombinant adeno-associated viral (rAAV) vectors for gene therapy 
applications have limitations related to their low transduction efficiency. For instance, in 
one study it was shown that only about 4%–5% of AAV2 particles attach to cell surface, 
and just 30% of them successfully reach the nucleus, meaning that eventually only 1%–
2% of AAV virions will enter the nucleus and express (Xiao et al. 2012). Many studies 
were carried out to understand the cellular transduction mechanisms of rAAV. Using this 
knowledge it would be possible to improve transduction of AAV vectors and thereby to 
increase efficiency of the gene therapy, and also to avert untoward toxicity and/or an 
immune response (Weinberg et al. 2014).  
First and the most critical step is entry and early trafficking of rAAV through the cell 
(Fig. 10). Cell-rAAV vector interaction starts from binding to glycan receptors (Huang et 
al. 2014), which leads to attachment of virions to the cell surface. Further cellular uptake 
is mediated by integrins and/or different transmembrane receptors (Berry & Asokan 
2016), including clathrin-mediated endocytosis (Duan et al. 1999; Bartlett et al. 2000), 
micropinocytosis (Weinberg et al. 2014) and through CLIC/GEEC endocytic pathway 
(Nonnenmacher & Weber 2011). The entry pathway does also depend on rAAV vector 
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serotype as well as on the host cell environment (Weinberg et al. 2014). Moreover, some 
of these pathways lead to successful transduction, however another pathways in the 
same cell may be the ‘dead end’ for rAAV vector (Berry & Asokan 2016).  
Once entering the cell AAV particles are conceivably trafficked to Rab5+ early 
endosome (Harbison et al. 2009). Further, rAAV vectors are trafficked to the Golgi 
apparatus in various ways: though Rab7+ late endosome, Rab11+ recycling endosome 
(Ding et al. 2006) or through syntaxin 5-dependent transport (Nonnenmacher et al. 
2015), which as is a case with cell entry, differ in a serotype or/and host cell type 
dependant manner.  
An important component which mediates rAAV transport through the 
endomembrane system to the trans-Golgi network (TGN) is so called AAV receptor 
(AAVR). This receptor largely localizes to Golgi apparatus and is essential for the 
efficient transduction (Pillay et al. 2016), however the mechanisms of AAVR mediated 
AAV transduction need to be further investigated.  
After AAV particle passed through vesicular and Golgi compartments, rAAV 
escapes the endosome into the cytosol in phosphorilaze-dependent manner 
(phosphorilazes PLA1 and PLA2).  
Nuclear import happens through the nuclear pore complex (NPC) mediated by 
importin-b1 (Nicolson & Samulski 2014). There are four basic regions (BR1-4) on rAAV 
conserved among serotypes 1–11, which are potentially playing function as nuclear 
localization signals (NLS). Upon nucleus entry to proceed with transgene expression 
rAAV particles need to be uncoated.  Upon release, AAV ssDNA genome undergoes 
second-strand DNA synthesis (Berry & Asokan 2016), and then being circularized and 
concatemerized (Choi et al. 2005)  by DNA recombination events. It was shown that 
several splicing factors, which belong to the U2 snRNP spliceosome complex, can bind 
to the exposed genome and the capsid, restricting processes starting from nuclear entry 
to second-strand DNA synthesis, eventually suppressing transcription (Schreiber et al. 
2015).  
The knowledge on rAAV transduction mechanisms will lead to development of 
various strategies to target the host factors that have been implicated in AAV trafficking 
and thereby to enhance the potency of rAAV vectors.  
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Figure 10. Summary of intracellular 
trafficking events leading to successful 
AAV transduction. 
Adapted from (Berry & Asokan 2016) 
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4. rAAV VECTOR PRODUCTION 
The most established method of production of rAAV particles is by co-infection of 
HEK293 cells by rAAV vector cloned into a plasmid and a plasmid carrying the AAV rep 
and cap genes (Grieger et al. 2006). Helper functions important for AAV successful 
replication could be supplied by co-transfecting cells with a helper virus, e.g., adenovirus, 
or either by co-transfecting with helper plasmid carrying genes from adenovirus (E4, E2a 
and VA). Notably, rep and cap genes can be supplied with helper genes within the same 
plasmid (Grimm et al. 1998). Double instead of triple- transduction has several 
advantages, including elimination of helper virus contamination in rAAV stocks as well 
as increased titres due to higher cell viability (Grimm et al. 1998; Ayuso et al. 2010). The 
replicating rAAV genomes are packed into pre-formed capsids within a nucleus of 
infected HEK293 cells. Cells are then harvested, homogenized and viral articles are 
purified from cell homogenate (Fig. 11).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Production of  recombinant AAV vector particles (Zacchigna et al. 2014). 
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5. IMMUNE RESPONSE TO rAAV 
Initially rAAVs were considered as non-immunogenic vectors due to their 
inefficiency in transducing antigen-presenting cells (APCs) in mice (Jooss et al. 1998). 
However when the first clinical trials were conducted, they showed that rAAV gene 
therapy in humans could actually activate innate and adaptive immune response to a 
viral capsid, a DNA genome and the therapeutic product of this transgene (Mingozzi & 
High 2013). Immune response can lead to clearance of transduced cells, therefore 
limiting the therapeutic efficacy of the gene therapy (Mingozzi et al. 2007). Different 
factors such a dose, the choice of AAV serotype and the administration route can 
influence the rAAV vector immunogenicity. More studies need to be done to understand 
how to influence the initiation of an expression limiting immune response, however the 
main obstacle is that so far there is no animal model that could recapitulate the human 
immune response to the viral vector, and the majority of the questions answered to date 
are based on information from clinical studies. 
Many efforts has been done to prevent immune response to rAAV vector. At the 
moment the most successful results are given by glucocorticoid steroid 
immunosuppressant drugs (Flanigan et al. 2013).   
It was shown that organism, in contrast with immune response, can also develop 
tolerance to rAAV vectors through induction of T regulatory response and silencing of T 
lymphocytes, however the mechanism of tolerance is still lacking precise 
characterization (Lin et al. 2007; Velazquez et al. 2009; Flotte et al. 2011; Mueller et al. 
2013). 
Summing up, even taking into account rAAV immune activating properties, they 
remain much reduced compared to other viral and non-viral vector.  
6. SAFETY CONCERNS OF rAAV GENE THERAPY 
AAV gene therapy possess a great potential for treating human diseases and is 
actively undergoing clinical trials, however the safety of AAV vectors still needs more 
detailed assessment. Even when designed to prevent site-specific integration, rAAV 
vectors at low frequencies but can integrate at non-homologous sites in the host genome. 
Integration happens into so-called “hot spots”, which represent sites of genomic 
instability and are prone to double-strand breaks or other forms of DNA damage, 
activating non-homologous recombination (Nakai et al. 2005; Inagaki et al. 2007; Deyle 
& Russell 2009). rAAV vector integration into genome may lead to insertional 
mutagenesis, altering the expression of chromosomal genes and even causing 
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malignant transformation (Nakai et al. 2005; Miller et al. 2005; Donsante et al. 2007; 
Deyle & Russell 2009), and therefore should be taken into account. However, the 
frequency of AAV vector genome integration is too low, which is one of the main 
advantages of AAV vectors, and therefore they are actively being tested in clinical trials  
(Anon n.d.; Vance et al. 2015).  
7. AAV SEROTYPES AND THEIR BIODISTRIBUTION 
Chronologically, a majority of the first discoveries and applications were associated 
with AAV serotype 2 (Srivastava et al. 1983), however over the last years, thirteen human 
serotypes of AAV (AAV serotype 1 [AAV-1] to AAV-13) (Srivastava 2016) and more than 
100 serotypes from nonhuman primates have been discovered and isolated (Daya & 
Berns 2008). Knowledge on different serotypes opens many opportunities, because 
serotypes were found to differ in infectivity rates and tissue specificity. Variability of 
serotypes is distributed within looped out domains, displayed on the surface of the capsid 
structure (Gao et al. 2003), which are primarily involved in cellular interactions. 
Therefore, these differences are more likely define differences between AAV serotypes 
in tropism and transduction efficiency. The efficacy ad tissue specificity of some of the 
AAV serotype vectors has been evaluated in different animal models (Fig. 12) 
(Srivastava 2016). 
AAV vectors share a high homology among different human serotypes (Vance et 
al. 2015), as well as have high similarity in sequences with non-human serotypes, which 
efficiently distribute and are able to cross various species barriers, making them also 
suitable for treating human disease (Vance et al. 2015).  
 
 
 
 
 
 
 Figure 12. Schematic representation of various studies carried out with AAV vectors of 
different serotypes in animal models and in humans (Srivastava 2016). 
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8. AAV9 SEROTYPE 
Recombinant AAV9 vector owns a list of beneficial properties, which makes it one 
of the most popular vectors used for therapeutic applications.            
First, AAV9 demonstrates one of the fastest onset and the highest expression of 
transgene as well as the best viral genome distribution among other serotypes upon 
systemic administration (Zincarelli et al. 2008). Superior to other serotypes it efficiently 
targets heart, liver and skeletal muscle (Bish et al. 2008; Inagaki et al. 2006; Pacak et al. 
2006; Zincarelli et al. 2008; Vandendriessche et al. 2007). AAV9 tissue binding was 
shown to be primarily mediated by N-linked glycans with terminal galactosyl residues, 
which are abundant in various animal tissues, explaining the broad tropism of AAV9 
serotype (Shen et al. 2011).  
Moreover, AAV9 is one of the few serotypes (together with AAV8 to the lesser 
extent), which possess the ability to cross blood-brain barrier following intravascular 
administration (Foust et al. 2009), opening up new opportunities for basic and clinical 
neurology studies. 
9. GENE THERAPY OF DISEASES AND AGING 
Five decades after the discovery of adeno-associated virus (AAV) and more than 
30 years since the first gene transfer experiment, to date over 183 clinical trials worldwide 
are in process what makes up 7.3 % of virus-vectored gene-therapy trials (Anon n.d.) 
(Fig. 13). 
 
 
 
 
 
 
 
 
 
 
Figure 13. Vectors Used in Gene Therapy Clinical Trials, 2017 (Anon n.d.) . 
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Extensive preclinical studies led to many clinical trials and to date one AAV vector 
is already approved for use in Europe (Anon n.d.; Ylä-Herttuala 2012; Scott 2015). Most 
of clinical trials, which are running today, are aimed to target broad types of diseases 
such as monogenic, inherited diseases, replacing defective gene (hemophilia A and B), 
neurological (Parkinson's disease, Canavan disease, Alzheimer’s disease), 
cardiovascular (congenital heart failure, cardiomyopathies), ocular (Leber congenital 
amaurosis) and infectious (HIV) diseases, muscular dystrophies as well as arthritis and 
cancer (scuamos cell head and neck cancer), etc (Vance et al. 2015). Recent pre-clinical 
studies have also demonstrated efficiency of using AAV vectors to target aging. 
Delivering TERT gene via rAAV gene therapy affected one of the hallmark of aging, 
telomere shortening, leading to telomere lengthening and decreased abundance of short 
telomeres, improving the life and health span in aging mice (Bernardes de Jesus et al. 
2012; Boccardi & Herbig 2012). Growing knowledge and application is showing a 
promising success of AAV gene therapy for different needs.  
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I. To study the dynamics of TRF1 expression in aging in vivo in mouse 
and human tissues 
II. To study potential effects of AAV9-TRF1 gene therapy in adult and 
old mice on aging 
1. To produce AAV9 vectors carrying mTrf1 transgene and confirm their 
transduction efficiency and TRF1 overexpression in various tissues 
2. To perform AAV9-TRF1 gene therapy in adult and old wild type mice 
and to study it effects on life span and health 
3. To study the molecular consequences of AAV9 mediated TRF1 
overexpression 
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1. MICE AND ANIMAL PROCEDURES 
Experiments were performed with wild type mice of a >95% C57BL/6 background. 
All of the data was collected in a quantitative way and subjective evaluations were not 
made. Mice were produced and housed in the specific-pathogen-free animal house of 
CNIO, Madrid. All procedures performed on mice were approved by the CNIO-ISCIII 
Ethics Committee for Research and Animal Welfare (CEIyBA). Mice were treated 
according to Spanish laws and the guidelines of the Federation of European Laboratory 
Animal Science Associations (FELASA). 
Mice were tail-vein injected with a dose of 2*1012 viral genomes per mouse– 
AAV9-TRF1 in the experimental group and AAV9-empty in the control group. Injections 
were performed at different ages: adult mice of ~1 year of age (64-65 weeks old) and old 
mice ~2 years of age (109-110 weeks old). Between different groups within the same 
age, an equal ratio males/females was maintained. 
2. RECOMBINANT AAV9 VECTORS  
Mouse TRF1 was cloned into pBABE puro plasmid vector at CNIO (Madrid), 
which was used for AAV9-TRF1 production. AAV9-TRF1 and control vectors were 
produced and purified as described previously (Matsushita et al. 1998; Ayuso et al. 
2010). Briefly, recombinant AAV9 vectors were produced through triple transfection of 
HEK293 cells by plasmid carrying a TRF1 expression cassette, plasmid carrying the AAV 
rep and cap genes, and an adenovirus helper plasmid. AAV9 vector purification was 
achieved by CsCl gradient centrifugation, following CsCl removal by dialysis against PBS 
and filtration. Titres of viral particles were determined by quantitative RT-PCR. 
3. RNA ISOLATION AND RT-QPCR  
Analysed tissues were homogenized and total RNA was isolated using the 
RNeasy Mini Kit (QIAGEN). The concentration and purity of the RNA was determined 
with a NanoDrop ND-1000 spectrophotometer. Total RNA was retrotranscribed using the 
iScript cDNA Synthesis Kit (Bio-Rad), according to the manufacturer's guidelines.  
Expression levels of Trf1 mRNA were determined by real-time PCR, performed using 
Power SYBR Green PCR Master Mix (Applied Biosystems) in an ABI 7900HT Fast Real-
Time PRC System (Applied Biosystems). Each reaction was performed in triplicate and 
normalized to GAPDH mRNA levels as an endogenous control. Sequences of the mouse 
primers used for quantitative real-time PCR in this work are listed: TRF1-Fw: 5’-TCT 
AAG GAT AGG CCA GAT GCC A-3’, TRF1-Rv: 5’-CTG AAA TCT GAT GGA GCA CGT 
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C-3’, GAPDH-Fw: 5’-TTC ACC ACC ATG GAG AAG GC-3’, GAPDH-Rv: 5’-CCC TTT 
TGG CTC CAC CCT-3’.  
4. IMMUNOFLUORESCENCE ANALYSIS  
Immunofluorescence analysis was performed on paraffin-embedded tissue 
sections as described previously (Tejera et al. 2010; Martínez et al. 2009). To target 
TRF1, a homemade rat monoclonal anti-TRF1 antibody and polyclonal goat anti-rat 
Alexa 555 as a secondary antibody were used. Images were captured on a confocal 
ultraspectral microscope Leica TCS-SP5-WLL. Fluorescence intensities were analyzed 
using Definiens Developer Cell software. 
5. BLOOD SAMPLES AND CELL COUNTS  
Blood samples were taken at different time points over the lifespan by facial vein 
puncture (~50 μL) and collected in EDTA anti-coagulant tubes. Blood cell counts, 
hematocrit (Hct) and hemoglobin (Hb) concentrations were measured on an Abacus 
Junior Vet veterinary hematology analyzer. 
6. HIGH-THROUGHPUT Q-FISH (HT Q-FISH) 
To perform a longitudinal study on telomere length dynamics in mouse peripheral 
white blood cells, blood samples were collected as described in the section above at the 
indicated time points after AAV9 injection. Blood samples were processed with 
erythrocyte lysis using Buffer EL (QIAGEN) and frozen in 10% DMSO/FBS. Prior to 
proceeding with the protocol, blood samples were de-frozen and plated in poly-L-lysine 
pre-coated clear bottom black-walled 96-well plates (Greiner). Samples were analyzed 
in duplicate. The HT Q-FISH protocol was performed as described in (Canela et al. 
2007). In order to convert telomeres fluorescence values into kb, we used standard cell 
lines with stable telomere length: L5178Y-R (79.7 kb), HeLa1211 (23.8 kb) and CCRF-
CEM (7.5 kb). Images were acquired on an Opera High Content Screening System 
(PerkinElmer, Inc.) and analyzed with Acapella Image analysis software (PerkinElmer, 
Inc.).  
7. TELOMERE Q-FISH ANALYSIS  
Telomere analysis was performed on paraffin-embedded tissue sections, which 
were de-parafinized, hybridized with a PNA-telomeric probe and treated as described in 
(Zijlmans et al. 1997). Images were captured on the confocal ultraspectral microscope 
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Leica TCS-SP5-WLL. Analysis of images was performed using the Definiens Developer 
Cell software. 
8. IMMUNO-FISH ANALYSIS 
To assess the level of DNA damage at telomeres, we performed Immuno-FISH 
analysis. First we performed a Q-FISH protocol excluding a pepsin digestion step, 
followed by an immunofluorescence protocol, using rabbit monoclonal anti-53PB1 
antibodies for the primary antibody and polyclonal goat anti-rabbit Alexa 488 antibodies 
for the secondary antibody. Images were acquired on a confocal ultraspectral 
microscope Leica TCS-SP5-WLL. Analysis of images was performed using the Definiens 
Developer Cell software.  
9. NEUROMUSCULAR COORDINATION  
Neuromuscular coordination and balance were evaluated in tightrope and rotarod 
tests. In the tightrope test, mice were placed onto a bar (100 cm long and 1.5 cm 
diameter). If the mouse was able to remain on the bar for 1 minute, it was considered as 
a success. Percentage of success out of five trials was determined. In the rotarod test, 
mice were placed onto a rod which was rotating with accelerating speed from 4 to 40 
rpm during one minute. The mean time of the latency before falling was measured in 3 
trials. 
10. MEMORY ANALYSIS  
Recognition memory was studied in the object recognition test as described in 
(Bevins & Besheer 2006). Each mouse was placed in a box to investigate two equal 
objects for 5 min. In a 2 h time gap one of the two objects was replaced with an object of 
different form and structure, and the mouse was placed back into the box for 5 more min. 
The memory score was quantified as the time spent investigating a novel object divided 
by the total time of investigation of both objects. 
11. SUBCUTANEOUS FAT THICKNESS  
Thickness of the subcutaneous fat layer was measured as described previously 
(Moynihan et al. 2005). Briefly, a total of 20 measurements were performed on 3 back 
sections of the skin for each mouse sacrificed at the humane end point. For these 
measurements, 17 AAV9-empty and 15 AAV9-TRF1 mice were used. Measurements 
were made using Panoramic Viewer software. 
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12. BONE MINERAL DENSITY 
Bone mineral density (BMD) was measured on anaesthetized living mice using a 
Dual Energy X-ray Absorptiometry (DEXA) scan device.  
13. INTRAPERITONEAL GLUCOSE TOLERANCE TEST (IP-GTT) 
To measure the clearance of injected glucose into peripheral tissues, an IP-GTT 
test was performed as described (Moynihan et al. 2005; Tomás-Loba et al. 2008). Briefly, 
mice were fasted for 14 h and then injected intraperitoneally with 50% D-(+)-glucose 
solution (2 g/kg body weight). Blood was collected from the tail vein at 0, 15, 30, 60, 90 
and 120 min after injection and blood glucose levels were measured with a glucometer 
and Glucocard Memory Strips (Arkray Factory, Inc., Japan). Glucose curves on changing 
of glucose levels with time were represented, and area under the curve (AUC) was 
calculated. 
14. FASTING INSULIN LEVELS AND HOMEOSTATIC MODEL ASSESSMENT 
OF INSULIN RESISTANCE (HOMA-IR) 
 Serum was taken from mice after 14 h of fasting. Insulin levels were measured in 
blood serum with an Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc.), 
following the manufacturer’s protocol.  
HOMA-IR was performed as described (Heikkinen et al. 2007a). HOMA-IR index 
was calculated according to the formula: 
 
HOMA − IR =
FPI × FPG
22.5 × 18 × 45.5
 
 
where FPI is the fasting serum insulin (ng/mL) determined by ELISA and FPG is 
the fasting blood glucose concentration (mg/dL). 
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1. TRF1 LEVELS DECREASE WITH INCREASING AGE BOTH IN MICE AND 
HUMANS 
To address whether the decrease of TRF1 is associated to physiological ageing in 
vivo, here we determined both mRNA and protein TRF1 levels in the epidermis of wild-
type mice at different ages including young (6-to-8 weeks old), adult (52-to-57 weeks 
old), and old mice (89-to-104 weeks old). We found significantly decreased Trf1 mRNA 
levels in the epidermis of adult and old wild-type mice compared to young mice (Fig. 1A). 
As an independent molecular marker of aging, we also measured p16 (a mediator of 
cellular senescence) mRNA levels, which are known to increase with age in almost all 
tissues in rodents and humans (Krishnamurthy et al. 2004; Satyanarayana & Rudolph 
2004). As expected, p16 mRNA levels were higher in the epidermis of middle-aged mice 
compared to young mice, and this was further increased in old mice (Fig. 1B).  
 
Earlier Dr. Ralph Schneider from our Group has shown decreased TRF1 protein 
expression levels in the mouse and human epidermis at different ages. Using 
immunofluorescence with antibodies against the TRF1 protein, he demonstrated that 
TRF1 fluorescence was significantly decreased in old mice compared to both adult and 
young mice (Fig. 2A). Importantly, TRF1 levels with aging were also decreased in the 
human epidermis. In particular, performing TRF1 immunofluorescence on human skin 
samples from young (2-to-12 years old), adult (31-to-40 years old), and old (75-to-85 
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Figure 1. Decrease of TRF1 mRNA levels with aging in mouse skin. 
(A-B)  Trf1 (A) and p16 (B) mRNA levels determined by RT-qPCR in tail skin epidermis from 
6, 57 and 89 weeks old mice. Trf1 and p16 mRNA values are normalized to GAPDH. Student’s 
t-test was used for statistical analysis. Error bars represent SEM. U.d.- undetermined value 
*p < 0.05; **p < 0.01; ***p < 0.001. n indicates the number of mice/individuals. 
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years old) individuals, he observed significantly decreased TRF1 levels with age. In 
particular, adult human skin showed significantly lower TRF1 levels compared to young 
skin, and TRF1 levels were further decreased in old skin samples (Fig. 1B).  
We extended these findings to the intestine, where we also observed a significant 
decrease in TRF1 protein levels in the old mice group compared to young mice group 
(Fig. 3A). In the case of post-mitotic tissues, we saw decreased TRF1 expression with 
aging in the muscle tissue in mice (Fig. 3B), but not in the liver (Fig. 3C).  
Figure 2. Decrease of TRF1 protein levels with aging in mouse and human skin. 
(A) Representative images of TRF1 (in red) and DAPI (in blue) and quantification of TRF1 
protein levels measured by immunofluorescence analysis in mice of 8, 52 and 104 weeks old 
in back skin epidermis. (B) Representative images of TRF1 (in red) and DAPI (in blue) and 
quantification of TRF1 protein levels measured by immunofluorescence analysis in skin 
epidermis of young (2-12 years), middle-age (31-40 years), and old (75-85) humans. Student’s 
t-test was used for statistical analysis. Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 
0.001. n indicates the number of mice/individuals. For each experiment, images were acquired 
with the same resolution and exposure parameters. 
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In summary, these findings indicate that TRF1 levels decrease with age in mice 
and humans, at least in the majority of tissues that have been studied here.   
 
 
 
 
 
2. AAV9-TRF1 VECTORS DEMONSTRATE HIGH TRANSDUCTION 
EFFICIENCY AND LEAD TO INCREASED TRF1 LEVELS IN MULTIPLE 
MOUSE TISSUES 
As TRF1 levels decrease with aging in mice and humans, we next set to study 
whether we could rescue phenotypes associated with aging in vivo by increasing TRF1 
expression in adult and old mice. As we previously described that constitutive TRF1 over-
expression in transgenic mice leads to XPF-dependent telomere shortening (Muñoz et 
al. 2009), here we set to over-express TRF1 in a moderate and transient manner. To this 
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Figure 3. Decrease of TRF1 protein levels with aging in mouse intestine and TRF1 
protein levels in post-mitotic tissues. (A) Representative images of TRF1 (in red) and DAPI 
(in blue) and quantification for TRF1 immunofluorescence analysis in mice of 8 weeks and 
106 weeks old in intestine. (B-C) Mean TRF1 protein levels in mice at young (8 weeks) and 
old (> 2 years) ages in muscle (B) and liver (C). Expression levels are presented as total 
intensity per nucleus. Student’s t-test was used for statistical analysis. Error bars represent 
SEM. *p < 0.05; **p < 0.01; ***p < 0.001. n indicates the number of mice. For each experiment, 
images were acquired with the same resolution and exposure parameters. 
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end, we used recombinant AAV vectors, which are non-integrative (Ayuso et al. 2010), 
thus leading to a transient TRF1 overexpression.  In particular, we used the AAV9 
serotype, also previously used by us to deliver the TERT telomerase gene to many 
different adult tissues in mice (Bär et al. 2014; Bar et al. 2016; Bernardes de Jesus et al. 
2012). AAV9 has a number of attractive properties such as poor immunogenicity, high 
transduction efficiency in a wide range of tissues, and the ability to cross the blood-brain 
barrier (Ayuso et al. 2010).  
First, to assess the efficiency of transduction and expression of the AAV9-TRF1 
vector, we intravenously injected 8.5 month-old mice with AAV9-TRF1 and 3 weeks post-
injection determined TRF1    mRNA and protein levels in various tissues (Fig. 4, 5A, 7). 
 
 Upon AAV9-TRF1 transduction we found significantly upregulated TRF1 mRNA 
levels in the liver, heart, muscle, and brain (Fig. 5A).  However, we did not see a 
significant increase of the rest of the shelterin components (Fig. 5B). We also found 
increased TRF1 mRNA levels in kidney, bone marrow, lung and intestine, although in 
these cases the differences did not reach significance (Fig. 5A). 
By using immunofluorescence analysis with anti-TRF1 antibodies, we confirmed 
TRF1 protein overexpression both when measuring mean TRF1 fluorescence levels and 
the percentage of nuclei with “high TRF1” levels. In particular, cells were designated as 
“high TRF1” if the TRF1 levels were above the 99th percentile determined from the control 
group (Fig. 6). 
 
1 2 3 0 
AAV9 IV Necropsy 
Week: Time post- injection 
(weeks) 
8,5 months 
Figure 4. Scheme of mice injection for the transduction efficiency study. 
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We found increased TRF1 protein levels in liver, heart, muscle, and lung, when 
using both parameters (Fig. 7). This pattern of overexpression of TRF1 using AAV9 is 
consistent with previous reports (Schuster et al. 2014; Zincarelli et al. 2008; Bernardes 
de Jesus et al. 2012). Thus, by using AAV9-TRF1 vectors we can efficiently deliver TRF1 
to different adult tissue types in the mouse. 
Muscle 
Figure 5. AAV9-TRF1 transduction efficiency, determined by RT-qPCR, and mRNA levels of other 
shelterins upon TRF1 overexpression.  
(A) Trf1 mRNA levels determined by RT-qPCR in several murine tissues injected with AAV9-TRF1 vector 
compared to mice injected with AAV9-empty vector (set to 1). 5 mice per group were used. Trf1 mRNA values 
are normalized to GAPDH. (B) Trf1, Trf2, Rap1, Tpp1, Tin2, Pot1a and Pot1b mRNA levels determined by 
RT-qPCR in muscle from mice injected at 1 year of age with AAV9-TRF1 compared to AAV9-empty 
determined at humane time point. Student’s t-test was used for statistical analysis. Error bars represent SEM. 
*p < 0.05; **p < 0.01; ***p < 0.001. n indicates a number of mice. 
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Figure 6. “High TRF1” nuclei designation. Histogram of the distribution of nuclei by their sum 
intensities calculated in muscle tissue of mice injected with AAV9-TRF1 and AAV9-empty. 
Nuclei with “High TRF1” levels are determined as nuclei with intensities above the 99th percentile 
of the control group. 
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Figure 7. TRF1 expression efficiency upon transduction via AAV9 vector. 
Representative images of TRF1 (in red) and DAPI (in blue) and quantification for TRF1 protein level and percentage 
of nuclei expressing “high TRF1” levels, measured by immunofluorescence analysis in various murine tissues in mice 
injected with AAV9-TRF1 vector compared to AAV9-empty vector (set to 1). Amplified images are shown in the insets. 
Student’s t-test was used for statistical analysis. Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. n 
indicates a number of mice. Within each tissue images were acquired with the same resolution and exposure 
parameters. 
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3. AAV9-TRF1 GENE THERAPY DELAYS PHYSIOLOGICAL MOUSE AGING 
To study whether AAV9-TRF1 treatment was able to delay aging and age-related 
phenotypes in mice, middle aged (1 year old) and old (2 years old) mice were 
intravenously injected with a single dose of either AAV9-TRF1 or AAV9-empty vectors. 
Upon treatment with the vectors, the mouse cohorts were longitudinally followed to 
determine different parameters of aging, cancer, as well as overall survival. Telomere 
length in blood samples was also determined longitudinally as a molecular biomarker of 
aging. At the humane end point mice were sacrificed and a full histopathological analysis 
was performed (Fig. 8). 
Neuromuscular coordination 
Progressive loss of neuromuscular function is a characteristic of aging (Ingram & 
Reynolds 1986). Thus, we first evaluated neuromuscular function in AAV9-TRF1 treated 
mice compared to AAV9-empty treated controls in 2 sets of experiments: the tightrope 
test and rotarod test. Mice treated with AAV9-TRF1 at 1 year of age showed a statistically 
significant improvement of neuromuscular coordination in the tightrope test at 7 months 
post-injection compared to controls treated with the empty vector, and this difference 
was maintained at later time-points although the results did not reach statistical 
significance (Fig. 9A). A similar trend was also observed in the 2-year old group although 
it did not reach significance (Fig. 9B). In the rotarod test, we also found a trend for 
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Figure 8. Scheme of mice injection for the study of effect of AAV9-TRF1 gene therapy on 
mouse aging. 
Two groups of mice were intravenously injected with AAV9-TRF1 or a control AAV9-empty 
vector (AAV9 VI) at two different ages: middle age (1 year old) and old (2 years old). Aging 
studies (      ) and blood sampling (   ) were longitudinally performed at different time points, 
indicated as months post-injection. Mice were sacrificed when they reached a humane end 
point and the full necropsy was performed. 
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improved performance in the 1-year old group treated with AAV9-TRF1 compared to the 
empty-vector treated group, although the differences did not reach significance (Fig. 9C). 
Thus, AAV9-TRF1 treatment improved neuromuscular coordination in the 1-year old 
group, and these differences were lower in the 2 year old group. 
Cognitive impairment 
As AAV9 vectors can cross the blood-brain barrier and we indeed found TRF1 
mRNA levels increased in the brain (Fig. 5A), we next investigated the effects of AAV9-
TRF1 gene therapy on cognitive function. To this end we used the so-called object 
recognition test, which is widely used to assess cognitive decline associated with aging 
(Fig. 10A) (Scali et al. 1997). At 5 months post treatment with AAV9-TRF1, 1-year old 
mice showed improvement in recognition memory scores compared to mice treated with 
the empty vector (Fig. 10B). We also observed improved cognitive function in the 2-year 
old mice treated with AAV9-TRF1 vectors at 2 month post-injection compared to mice 
treated with the empty vector (Fig. 10C). Thus, AAV9-TRF1 gene therapy significantly 
ameliorates memory scores in both the 1 year old and 2 year old groups. 
 
Figure 9. AAV9-TRF1 gene therapy improves neuromuscular coordination.  
(A-B) Neuromuscular coordination using tightrope test in 1 year old (A) and 2 years old (B) mice injected with 
AAV9-TRF1 compared to AAV9-empty vector. (C) Neuromuscular coordination using rota-rod test in 1 year 
old mice. Time-points at time post-injection (PI) are indicated. Student’s t-test was used for statistical analysis. 
Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. n indicates the number of mice. 
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Skin aging 
Another characteristic of aging is the loss of the subcutaneous fat layer,  which 
increases the risk of skin injury, reduces the ability to maintain body temperature, and 
raises the probability of infection (Shimokata et al. 1989). Thus, we measured the 
thickness of the subcutaneous fat layer at the time of death of mice in the 2 year-old 
group.  Interestingly, mice from the 2 year-old group treated with AAV9-TRF1 showed a 
significantly thicker fat layer than the empty vector treated controls at their time of death 
(Fig. 11A-B), again showing a beneficial effect of AAV9-TRF1 therapy. 
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Figure 10. AAV9-TRF1 gene therapy improves memory scores. 
(A) Design of the object recognition test. (B-C) Object recognition test in 1 year old (B) and 2 
years old (C) mice. Results show the ratios of time spent investigating the new object vs. the 
total time spent with both objects. Time-points at time post-injection (PI) are indicated. Student’s 
t-test was used for statistical analysis. Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 
0.001. n indicates the number of mice. 
 
 
Figure 11. AAV9-TRF1 gene therapy delays age-associated subcutaneous fat loss. 
(A) Representative hematoxylin-eosin images of a back skin section of AAV9-empty and AAV9-
TRF1 injected mice. In the image of the AAV9-empty injected mouse, black arrows indicate 
residual adipocytes. In the image of the AAV9-TRF1 injected mouse, a black arrow indicates a 
subcutaneous fat layer. (B) Thickness of the subcutaneous fat layer of mice injected with AAV9-
empty and AAV9-TRF1 at 2 years old at the time of death. Student’s t-test was used for 
statistical analysis. Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. n indicates 
the number of mice. 
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Age-related osteoporosis 
Bone deterioration is a well-characterized sign of the aging process both in mice 
and humans (Ferguson et al. 2003). It results from age related shift of the bone 
homeostasis to the direction of the bone resorption by osteoclasts, leading to 
osteoporosis and a high risk to bone fractures (Demontiero et al. 2012). As expected, we 
observed a significant decline of bone mineral density (BMD) with age, measured in 
femur (Fig. 12A), when monitoring mice injected with the empty vector at 1 year of age 
over a long period of time (Fig. 12B). However, we did not observe any changes when 
treating mice with AAV9-TRF1 vector at both aging cohorts (Fig. 12C), meaning that 
TRF1 gene therapy does not affect bone homeostasis under these experimental 
conditions.  
 
Age related anemia 
Blood chemistry and composition vary with the aging process. Anemia is a 
common chronic condition appearing with age (Ferrucci & Balducci 2008; Berliner 2013; 
Patel 2008). Anemia can be caused by various age-related events occurring in the 
organism, such as telomere shortening (Herrera et al. 1999; Beier et al. 2012). Thus, to 
Figure 12. AAV9-TRF1 gene therapy does not prevent age-related osteoporosis. 
(A) Representative image of a DEXA scan for measurements of bone mineral density in femur 
(framed in green) (B-C) Femur bone mineral density (BMD femur) measured in 1 year old (B) 
and 2 years old (C) mice. Time-points at time post-injection (PI) are indicated. Student’s t-test 
was used for statistical analysis. Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. 
n indicates the number of mice. 
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study the effects of AAV9-TRF1 treatment on blood changes with age, we followed 
longitudinally red blood cell (RBC) counts in both the AAV9-TRF1 and AAV9-empty 
treated cohorts. To this end, we collected blood at different time points in both groups of 
mice. As expected, we found a decline in RBCs with age in both 1 year and 2 year-old 
groups treated with the empty vector (Fig. 13A, 13D). We also found a decrease in 
hemoglobin (Hb) and hematocrit (Hct) levels in both age groups (Fig. 13B-C, 13E-F). 
Interestingly, mice treated with AAV9-TRF1 at 1 year of age showed significantly higher 
RBC counts compared to the control at late time points (Fig. 13A). Analogous 
improvement was also noticed in the hemoglobin (Fig. 13B) and hematocrit (Fig. 13C) 
levels. A similar trend was also observed in mice injected at 2 years of age, although 
differences did not reach statistical significance in this old group (Fig. 13D-F). These 
observations suggest that AAV9-TRF1 treatment improves the chronic anemia condition 
acquired during mouse physiological aging. 
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Figure 13. AAV9-TRF1 gene therapy rescues age-related anemia. 
(A-F) Blood analysis for mice injected with AAV9 vectors at 1 year old (A-C) and at 2 years old (D-F). Red 
blood cell count (RBC) changes (A, D), hemoglobin levels (g/dl) (B,E) and hematocrit percentage (C, F). 
Time-points at time post-injection (PI) are indicated. Student’s t-test was used for statistical analysis. Error 
bars represent SEM. n indicates the number of mice. 
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Glucose Intolerance  
Glucose homeostasis likewise becomes dysregulated with age (Bailey & Flatt 
1982). An association of impaired insulin secretion and glucose intolerance with short 
uncapped telomeres has been established (Kuhlow et al. 2010). In particular, short or 
dysfunctional telomeres trigger a DNA damage response, which can lead to cellular 
senescence of adult islet beta-cells, thus resulting in dysregulation of insulin secretion. 
Here, we studied whether AAV9-TRF1 treatment can provide better telomere protection 
and decrease glucose homeostasis dysregulation associated with physiological aging. 
To assess glucose tolerance, we performed an intraperitoneal glucose tolerance test (IP-
GTT). We observed a significant improvement in glucose tolerance at 10 months post-
injection in the 1-year old AAV9-TRF1 treated mice compared to control mice treated 
with the empty vector (Fig. 14A-F).  
The same tendency was seen in the fasting insulin level, which is considered to be 
an indicator of insulin resistance and this level increases with age (Lindberg et al. 1997). 
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Figure 14. AAV9-TRF1 gene therapy delays glucose homeostasis dysregulation. 
(A-F) Intraperitoneal glucose tolerance test (IP-GTT) performed on mice injected with AAV9-
TRF1 and AAV9-empry at 1 year of age. Glucose curves before injection (A), at 4 months post-
injection (B), 10 months post-injection (C), 13 months post-injection (D), 14 months post-
injection (E) and AUC (area under the curve) values at these time-points (F) are represented. 
Student’s t-test was used for statistical analysis. Error bars represent SEM. *p < 0.05; **p < 0.01; 
***p < 0.001. n indicates the number of mice. 
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Levels of fasting insulin showed a lower trend in AAV9-TRF1 injected mice compared to 
controls at late time points post-injection (Fig. 15A). Finally, AAV9-TRF1 injected mice 
also showed a trend of improvement in homeostatic model assessment (HOMA-IR) 
compared to control mice treated with the AAV9-empty vector (Fig. 15B), again 
suggesting improved insulin sensitivity in the AAV9-TRF1 treated cohorts (Heikkinen et 
al. 2007b). Together, these findings suggest that AAV9-TRF1 gene therapy can improve 
glucose intolerance associated with age 
Correlation of TRF1 overexpression levels in mice with their performance in aging 
studies 
To study whether the mice expressing high levels of TRF1 were also the ones 
showing less age-related pathologies, we determined the percentage of cells showing 
high TRF1 expression in muscle. We found that the percentage of cells with high TRF1 
expression moderately correlated with improvement in the tightrope test (R=0.59; Fig. 
16A) as well as in the object recognition test (R=0.51; Fig. 16B).  There was also a strong 
correlation between the % of cells with high TRF1 expression and red blood cell counts 
(R=0.98; Fig. 16C) but not with the AUC in the glucose tolerance test (Fig. 16D). 
 
 
Data 1
AAV9-nullAAV9-Trf1AAV9-Trf2AAV9-Tpp1AAV9-nullAAV9-Trf1AAV9-Trf2
0
2
4
6
8
H
O
M
A
-I
R
Data 1
AAV9-nullAAV9-Trf1AAV9-Trf2AAV9-Tpp1AAV9-nullAAV9-Trf1AAV9-Trf2
0.0
0.5
1.0
1.5
2.0
2.5
In
s
u
lin
 l
e
v
e
ls
 (
n
g
/m
L
)
n=5 
n=5 
n=5 
n=8 
n=8 n=8 
p=0.327 
n=8 
n=7 
n=8 
n=5 
n=5 
n=5 
p=0.328 
Before I 4 months PI  10 months PI Before I 4 months PI  10 months PI 
A B 
Figure 15. Effects of AAV9-TRF1 gene therapy on insulin sensitivity. 
(A) Fasting insulin levels measured in AAV9-TRF1 mice compared to controls, injected at 1 year 
of age before injection, at 4 and 10 months post-injection. (B) HOMA-IR assessment using 
previous data on IP-GTT and on fasting insulin levels. Student’s t-test was used for statistical 
analysis. Error bars represent SEM. n indicates the number of mice. 
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4. AAV9-TRF1 TREATMENT IS NOT LEADING MICE TO BE TUMOR PRONE 
 Increasing age is the highest risk factor for cancer development both in humans 
and mice (White et al. 2014; Pawelec 2017). Furthermore, evidence suggests that TRF1 
overexpression may favour tumorigenesis. TRF1 is upregulated in some human cancers 
(Matsutani et al. 2001; Oh et al. 2005). Moreover constitutive TRF1 over-expression in 
epithelial tissue on transgenic mice (K5TRF1 mice) led to moderately increased levels 
of chromosomal aberrations and chemically induced skin tumorigenesis (Muñoz et al. 
2009). Therefore, we addressed effects of TRF1 increased expression in our 
experimental settings on tumor formation with aging. To assess the effects of AAV9-
TRF1 gene therapy on cancer incidence, we performed a full pathological analysis at the 
time of death in both AAV9-TRF1 and AAV9-empty treated mouse cohorts. Mice treated 
with AAV9-TRF1 at 1 and at 2 years of age showed a tendency to show lower cancer 
incidence compared to the empty-vector treated mice, although the differences did not 
reach significance (Fig. 17A-B). This illustrates that increased TRF1 expression is not 
rendering these mice to be tumor prone. 
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Figure 16. Correlation between percentage of nuclei overexpressing high TRF1 levels and readouts of aging. 
(A-D)  Correlation analysis between percentage of nuclei overexpressing high TRF1 levels and readouts of aging: success 
in tightrope test (A), memory function (B), RBC counts (C) and glucose tolerance (D). R indicates correlation coefficient. 
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Figure 17. AAV9-TRF1 treatment does not affect cancer incidence in aging mice. 
(A-B) Percentage of mice which developed tumors, for mice injected at 1 year (A) and at 2 years (B) of age. 
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5. AAV9-TRF1 TREATMENT DOES NOT AFFECT MEDIAN SURVIVAL 
Another indication of absence of deleterious secondary effects associated to 
increased TRF1 expression is provided by the fact that median survival did not differ 
between control and AAV9-TRF1 treated mice in any of the age groups (Fig. 18A-B). 
Interestingly, mice injected with AAV9-TRF1 at 2 years of age showed increased 
maximum lifespan compared to the controls when comparing the longest-lived mice in 
each cohort (Fig. 18B). 
6. AAV9-MEDIATED TRF1 OVEREXPRESSION IS MAINTAINED WITH AGE 
Previous reports have shown that AAV9 vectors allow for a long-term expression 
of the genes that they carry (Nizzardo et al. 2015; Bernardes de Jesus et al. 2012). To 
address whether AAV9-TRF1 treatment allowed for long term TRF1 expression, we 
compared TRF1 mRNA and protein levels at the humane endpoint in our 2-year old 
mouse cohort in which all mice had been already sacrificed. We found significantly higher 
TRF1 mRNA levels in the pancreas of AAV9-TRF1 treated mice compared to the controls 
(Fig. 19A). We also found significantly higher TRF1 protein levels as determined by 
immunofluorescence in several mouse tissues, such as liver and muscle (Fig. 19B-C).  
Interestingly, in agreement with the fact that AAV9 vectors are non-integrative and dilute 
as the cells divide, we noticed a decreased concentration of AAV9-TRF1 targeted cells 
with aging in all tissues (Fig. 6, 19E-F), suggesting that even though TRF1 
overexpressing cells are present, they are present in lower numbers as the tissues age. 
For this reason, we set to calcule the percentage of nuclei expressing high TRF1 levels, 
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Figure 18. AAV9-TRF1 treatment does not affect median life span in aging mice. 
(A-B) Survival curves for mice injected with AAV9-TRF1 compared to AAV9-empty vectors at 1 
year (A) and 2 years (B) old. The determined difference in maximum survival for the 10% longest 
lived mice for mice injected at 2 years of age. Student’s t-test was used for statistical analysis. 
n indicates the number of mice. 
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which reflects the cells maintaining high TRF1 expression at different time points. In most 
of the tissues analyzed, we identified significantly higher abundance of nuclei with “high 
TRF1” levels in AAV9-TRF1 injected mice compared to the controls (Fig. 19B-F). Thus, 
in muscle tissue of mice injected at 1 year of age where we could not detect any 
difference comparing mean TRF1 levels between the AAV9-TRF1 treated mice and the 
empty-vector controls. We readily detected a highly significant increase in “high TRF1” 
nuclei in the AAV9-TRF1 treated mice compared to the controls, confirming that at late 
time points TRF1 is still overexpressed (Fig. 19E), however in fewer cells than at earlier 
time points (Fig. 7). 
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Figure 19. Sustained TRF1 overexpression upon AAV9-TRF1 treatment in mice. 
(A) Trf1 mRNA levels determined by RT-qPCR in pancreatic tissue in mice injected at 2 years of age with AAV9-
TRF1 vector compared to mice injected with AAV9-empty vector (set to 1). Trf1 mRNA values are normalized to 
GAPDH. (B-D) Representative images of TRF1 (in red) and DAPI (in blue), mean TRF1 expression levels and 
percentage of “high TRF1” nuclei in mice injected with AAV9-empty and AAV9-TRF1 vectors at 2 years of age 
measured at the humane end-point in liver (B), muscle (C) and brain (D). (E-F) Representative images of TRF1 (in 
red) and DAPI (in blue), mean TRF1 expression levels and percentage of “high TRF1” nuclei in mice injected with 
AAV9-empty and AAV9-TRF1 vectors at 1 year of age, measured at the humane end-point in muscle (E) and brain 
(F). Expression levels are presented as total intensity per nucleus. Student’s t-test was used for statistical analysis. 
Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. n indicates the number of mice. 
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7. AAV9-TRF1 GENE THERAPY DOES NOT HAVE NEGATIVE EFFECTS ON 
TELOMERE LENGTH AND PROVIDES PROTECTION FROM THE 
ACCUMULATION OF SHORT TELOMERES  
Next, we set to address the long-term effects of AAV9-TRF1 gene therapy on 
telomere length. We first performed a longitudinal study on telomere length dynamics in 
blood peripheral leukocytes using the high-throughput Q-FISH (HT Q-FISH) technique. 
We did not observe any significant difference in the mean telomere length or percentage 
of short telomeres between 1-year-old injected experimental mice and the control groups 
not in PMBC (Fig. 20A-B) neither in other tissues (Fig. 21B-C). 
Q-FISH performed on muscle tissue of mice injected at 2 years of age also didn’t 
show any difference in the mean telomere length (Fig. 21A). Interestingly, the 
percentage of short telomeres, determined here within a control group as telomeres with 
intensities lower than the 25th percentile, was lower in muscle tissue of mice injected with 
AAV9-TRF1 compared to controls (Fig. 21A). These results highlight that TRF1 
overexpression through AAV9-TRF1 gene therapy does not trigger XPF-mediated 
telomere shortening, as it was observed in the case of constitutive TRF1 overexpression 
in a transgenic mouse model (Muñoz et al. 2009). Moreover, TRF1 overexpression in 
muscle tissue led to better protection of telomeres, delaying the accumulation of the short 
telomeres. 
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Figure 20. AAV9-TRF1 gene therapy has no effect on mean telomere length and number 
of short telomeres in peripheral white blood cells.  
(A-B) Characterization of telomere length measured by high-throughput Q-FISH (HT Q-FISH). 
Comparison of mean telomere length (A) and percentage of short telomeres (B) measured in 
peripheral white blood cells in mice injected at 1 year of age with AAV9-TRF1 vector compared 
to the control. Time-points at time post-injection (PI) are indicated Student’s t-test was used for 
statistical analysis. Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. n indicates 
the number of mice. 
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Figure 21. AAV9-TRF1 gene therapy has no effect on mean telomere length and rescues accumulation of 
short telomeres in mouse tissues. 
(A-B) Representative images of telomere probe Cy3 (in red) and DAPI (in blue) and quantification of telomere 
length and percentage of short telomeres measured in muscle in mice injected with virus vectors at 2 years of age 
(A) and in brain of mice injected at 1 year of age (B). (C) Quantification of telomere length and percentage of short 
telomeres measured in mice injected with virus vectors at 1 year of age determined in liver, kidney, lung, heart, 
pancreas, spleen. Analysis performed at the time of death. Student’s t-test was used for statistical analysis. Error 
bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. n indicates the number of mice. 
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8. AAV9-TRF1 INCREASES TELOMERE PROTECTION IN THE 
HIPPOCAMPUS AREA OF THE BRAIN OF MICE  
Based on the finding that AAV9-TRF1 gene therapy was able to delay the 
accumulation of short telomeres, we further addressed the question of whether it also 
prevents DNA damage at dysfunctional telomeres. Since an improvement in recognition 
memory was observed, the hippocampus was further investigated.  The hippocampus is 
a brain structure that plays a central role in the formation of new memories (Cohen & 
Eichenbaum 1993). The hippocampus exhibits neurogenesis, which continues through 
adulthood in a substructure named the dentate gyrus (Gross 2000). Aging and other 
conditions affect processes of neurogenesis, and this leads to impairment of cognitive 
function (Drapeau et al. 2003; Jin et al. 2003). As TRF1 is important for telomere 
protection, and moreover plays a role in stem cell function, we proposed that its 
deficiency may have molecular consequences and affect the stem cell pool of the dentate 
gyrus, thus leading to impaired neurogenesis and memory with age. In this case, AAV9-
TRF1 gene therapy may rescue this impairment to some extent.  
We first compared the DNA damage status in the brain of mice injected with AAV9-
TRF1 and control vector at the adult age. Total DNA damage was determined as area 
covered by 53BP1 foci. We did not observe any difference in total DNA damage in the 
whole brain, neither in the dentate gyrus area or the hippocampus (Fig. 22A-D). Next, 
DNA damage at telomeres was determined by immuno-FISH analysis as the number of 
TIFs (Telomere Dysfunction Induced Foci) – spots of co-localization of 53BP1 foci and 
telomere probe Cy3 foci. Although we did not see differences in whole brain sections 
(Fig. 22A, 22E), we observed significantly less TIFs in the dentate gyrus of mice treated 
with AAV9-TRF1 gene therapy compared to the empty-vector group (Fig. 22B, 22F). 
Thus, AAV9-TRF1 gene therapy seems to prevent DNA damage at telomeres in the 
dentate gyrus, which may have led to the improvement of the memory function observed 
in the object recognition test (Fig. 10B-C). 
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Figure 22. AAV9-TRF1 gene therapy reduces DNA damage levels at telomeres in the brain. 
(A-B) Representative images for immuno-FISH analysis on DNA damage and telomere-associated 
DNA damage in the whole brain (A) and specifically in the dentate gyrus of the hippocampus (B). 
Cy3 probe is presented in red, 53BP1 in green, and DAPI in blue. The representative images are 
merged from the Z-stack of images. Co-localization events (white arrows) were only counted as 
positive when detected in the individual confocal images. (C-D) Analysis of total DNA damage 
determined as the total intensity of 53BP1 foci per nucleus in the whole brain (C) and in the dentate 
gyrus area (D). (E-F) Analysis of telomere-induced DNA damages determined as the number of Cy3-
53BP1 co-localization events per cells in the whole brain (E) and the dentate gyrus zone (F). Analysis 
performed at the time of death. Student’s t-test was used for statistical analysis. Error bars represent 
SEM. *p < 0.05; **p < 0.01; ***p < 0.001. n indicates the number of mice. 
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9. CONTRIBUTING AUTORS  
 
Ralph P. Schneider 
Decreased TRF1 protein levels in the mouse and human epidermis (Fig. 2A-B). 
 
Kurt Whittemore 
TRF1 immunofluorescence in post-mitotic tissues (muscle and liver) in mice at young (8 
weeks) and old (> 2 years) ages (Fig. 3B-C). 
 
RT-qPCR to measure Trf1, Trf2, Rap1, Tpp1, Tin2, Pot1a and Pot1b mRNA levels in 
order to study effects of AAV9-TRF1 gene therapy on other shelterins (Fig. 5B). 
 
Immunofluorescence analysis in order to measure telomere length and percentage of 
short telomeres in liver, kidney, lung, heart, pancreas and spleen of mice injected with 
virus vectors at 1 year of age. (Fig. 21C). 
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TRF1 is a central component of the shelterin complex, with an important role in 
telomere protection (Smith & de Lange 1997; Palm & de Lange 2008; Diotti & Loayza 
2011). TRF1 also marks and is essential for both adult stem cells and pluripotent cells 
(Schneider et al. 2013). Interestingly, TRF1 levels decrease with increasing cell 
passages in vitro (Hohensinner et al. 2016), suggesting that TRF1 levels may also 
decrease with organismal aging.  
Here we for the first time show that TRF1 levels decrease during mouse and 
human aging in vivo. This poses the interesting hypothesis that reduced TRF1 levels 
with aging may lead to telomere uncapping and telomere-induced DNA damage 
(Martínez et al. 2009; Sfeir et al. 2009), as well as to loss of tissue homeostasis 
(Schneider et al. 2013), eventually leading to tissue dysfunction and organismal aging.  
To test this hypothesis, here we set to rescue TRF1 levels in aging by overexpressing 
TRF1 in adult and old mice. Our Group previously described that constitutive transgenic 
overexpression of TRF1 results in telomere shortening in vivo (Muñoz et al. 2009).  To 
overcome this problem, and to achieve a transient over-expression of TRF1, we used 
adeno-associated gene therapy vectors. As recombinant AAV9 vectors are non-
integrative and can transduce the majority of mouse tissues, they provide transient 
overexpression of the target protein in several mouse tissues (Ayuso et al. 2010).  
We describe here that mice treated with AAV9-TRF1 gene therapy showed 
significant improvements in health span, such as delayed anemia, and improvements in 
neuromuscular coordination, memory, epithelial barrier fitness, and glucose metabolism. 
Importantly, overexpression of TRF1 by using AAV9 vectors did not trigger telomere 
shortening.  
The AAV9-TRF1 therapy affected TRF1 levels in post-mitotic tissues, and this may 
contribute to the effect of TRF1 gene therapy on aging.  Although many of the cells in 
post-mitotic tissues do not proliferate, these tissues also contain stem cell compartments, 
which are responsible for maintaining tissue homeostasis throughout life. This is the case 
in the brain, the heart, and the muscle. For example, the brain exhibits neurogenesis, 
which continues throughout adulthood (Gross 2000). Muscle tissue in turn contain 
multipotent satellite cells, which are present in a quiescent state, but can be are activated 
and re-enter the cell cycle. They are indispensable for tissue growth and regeneration. 
Impaired function of satellite cells affects regenerative capacity of muscle tissue. 
Importantly, it was previously demonstrated that stem cell compartments exhibit 
increased TRF1 expression and that TRF1 is necessary for tissue homeostasis even in 
the presence of a normal telomere length (Martínez et al. 2009; Schneider et al. 2013). 
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Thus, TRF1 loss even in the presence of long telomeres can trigger severe defects in 
tissue homeostasis. Note that in our group it was previously demonstrated through whole 
genome ChIP-sequencing that TRF1 binding is restricted to telomeres and this is not 
influenced by shorter telomeres owing to telomerase deficiency (Garrobo et al. 2014). 
Therefore, it is unlikely that transient increased TRF1 expression owing to AAV9-TRF1 
gene therapy may have major effects on gene expression elsewhere in the genome.  
This is in contrast to other shelterin components like RAP1, which can affect gene 
expression and this effect is influenced by telomere length (Ye et al. 2014; Martinez et 
al. 2010).  We show here that TRF1 levels decrease with mouse aging in both highly 
proliferative tissues such as the skin and intestine, as well as in some post-mitotic tissues 
such as muscle. Since the deficiency of TRF1 leads to impaired telomere protection, this 
loss may play a role in age-associated impairments in the stem cell compartments as 
well. In addition, other processes associated with aging such defective DNA repair 
mechanisms could also result in de-protected telomeres (Grach 2013; Goytisolo et al. 
2001; Samper et al. 2000; Espejel, Martín, et al. 2004; Espejel, Klatt, et al. 2004; 
Tarsounas et al. 2004).  
In more details, we observed that AAV9 mediated TRF1 overexpression delayed 
accumulation of the short telomeres in muscle tissue. It is known that intracellular 
damage accumulated with age impairs the function of satellite cells, affecting the 
regenerative capacity of muscle tissue and contributing to development of sarcopenia, 
or age-related muscle wasting, which affects stability and balance (Ryall et al. 2008). 
This is consistent with our observations in neuromuscular coordination tests, where 
performance of the control group in tightrope test was impaired with age. Therefore 
evidence suggests that delayed accumulation of short telomeres upon AAV9-TRF1 gene 
therapy plays a role in improvement in neuromuscular coordination tests. 
Interestingly, we observed less telomere-associated DNA damage foci upon gene 
therapy in the hippocampus area of the brain. Previous reports showed that age-
associated accumulation of DNA damage in the hippocampus leads to impaired 
neurogenesis (Lemaire et al. 2000) and causes age-related cognitive alterations such as 
impaired memory function (Drapeau et al. 2003). In this regard, the improved memory 
scores observed here upon AAV9-TRF1 treatment, may suggest that AAV9-TRF1 gene 
therapy can delay age-related decline in hippocampal neurogenesis (Nacher et al. 2003; 
Drapeau et al. 2003; Lemaire et al. 2000), thus improving memory performance.  
The effect of TRF1 on telomeres appears to be influenced by the level of TRF1 
expression.  In a publication of our Group (Muñoz et al. 2009),  TRF1 was highly over-
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expressed in a constitutive manner over the lifetime of mice. This persistent TRF1 over-
expression lead to telomere shortening mediated by the XPF nuclease.  However, in this 
work, TRF1 is transiently expressed through AAV9-TRF1 gene therapy. After a single 
injection of these non-integrative vectors, the TRF1 signal becomes diluted with time in 
replicative tissues. Therefore, the levels of TRF1 overexpression achieved are much 
lower. As demonstrated here, the levels of TRF1 overexpression needed to negatively 
regulate telomere length are not reached after the TRF1 gene therapy as telomere 
shortening was not observed.  Indeed, we observed fewer short telomeres and telomere-
associated DNA damage in some tissues, which is consistent with in vitro data showing 
beneficial effects of TRF1 overexpression in aged cells (Hohensinner et al. 2016). 
Regarding, how TRF1 stabilizes telomeres, our Group have previously demonstrated 
that persistent TRF1 downregulation in bone marrow stem cells can lead to cellular 
senescence of stem cells and to a compensatory hyperproliferation of the remaining 
stem cells to maintain tissue homeostasis. This compensatory hyperproliferation also 
leads to telomere shortening (Beier et al., Blood, 2012). Thus, decreased TRF1 levels 
with aging may also lead to loss of stem cells and the extra proliferation of the remaining 
progenitor cells, thus leading to telomere loss. Increased TRF1 expression may 
attenuate this. 
In conclusion, we describe here an age-related loss of one of the key elements of 
telomere protection, TRF1. We further demonstrate that TRF1 decreased levels 
contribute to the aging phenotype, at least partially. In particular, transient and moderate 
TRF1 overexpression using recombinant adeno-associated viral vectors leads to 
beneficial effects both on molecular and physiological levels, ensuring better telomere 
protection and a prolonged health span. 
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CONCLUSIONS 
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1. TRF1 levels decrease with increasing age both in mice and humans. 
2. AAV9-TRF1 vectors demonstrate high transduction efficiency and lead to 
increased TRF1 levels in multiple mouse tissues. 
3. AAV9-TRF1 gene therapy delays physiological mouse aging. Namely, 
AAV9-TRF1 gene therapy prevents age-related decline in neuromuscular 
coordination, glucose tolerance, cognitive function, maintenance of 
subcutaneous fat, and chronic anemia. 
4. AAV9-TRF1 treatment is not leading mice to be tumor prone and does not 
affect median survival. 
5. AAV9-mediated TRF1 overexpression is maintained with age. 
6. AAV9-TRF1 gene therapy does not have negative effects on telomere 
length and provides protection from the accumulation of short telomeres. 
7. AAV9-TRF1 increases telomere protection in the hippocampus area of the 
brain of mice.  
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CONCLUSIONES 
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1. Los niveles de TRF1 disminuyen al aumentar la edad, tanto en ratones 
como en humanos. 
2. Los vectores AAV9-TRF1 demuestran una alta eficacia de transducción y 
conducen a niveles aumentados de TRF1 en múltiples tejidos de ratón. 
3. La terapia génica con AAV9-TRF1 retrasa el envejecimiento fisiológico del 
ratón. En este sentido, la terapia génica con AAV9-TRF1 previene la 
disminución relacionada con la edad en la función neuromuscular, la 
tolerancia a la glucosa, la función cognitiva, el mantenimiento de la grasa 
subcutánea y la anemia crónica. 
4. El tratamiento con AAV9-TRF1 no hace que los ratones sean propensos 
a tumores y no afecta la supervivencia media. 
5. La sobreexpresión de TRF1 mediada por AAV9 se mantiene con la edad. 
6. La terapia génica con AAV9-TRF1 no tiene efectos negativos en la 
longitud de los telómeros y proporciona protección contra la acumulación 
de telómeros cortos. 
7. AAV9-TRF1 aumenta la protección de los telómeros en el área del 
hipocampo del cerebro de los ratones. 
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